Table 1

Subject characteristics

T1D subjects
Before islet
transplantationAfter islet
transplantationNondiabetic control subjects
Male/female sex (n)5/75/74/4
Age (years)45 ± 347 ± 3**44 ± 3
Weight (kg)71 ± 365 ± 3**77 ± 5
BMI (kg/m2)25 ± 123 ± 1**25 ± 1
HbA1c (%)a7.1 ± 0.25.6 ± 0.1**5.5 ± 0.1**
T1D duration (years)29 ± 431 ± 4**
Insulin use (units ⋅ kg−1 ⋅ day−1)0.48 ± 0.050.06 ± 0.05**
IE/kg transplanted9,648 ± 666
Tacrolimus (μg/L)4.3 ± 0.4
Sirolimus (μg/L)b8.4 ± 0.5
Clarke scorec6.3 ± 0.20.4 ± 0.3**
HYPO scored2,564 ± 715ND
Lability indexe719 ± 6793 ± 56**
  • Data are mean ± SE. IE/kg, islet equivalent (whereby an islet equivalent approximates a standard islet diameter of 150 μm) transplanted per kilogram of recipient body weight; ND, not done.

  • aTo convert to mmol/mol, multiply by 10.93 and subtract 23.50.

  • bOne subject was converted from sirolimus to mycophenolate mofetil as a result of the development of interstitial pneumonia 4 weeks after transplant that subsequently resolved (9).

  • cClarke score of hypoglycemia unawareness (7 = most, 0 = none) (12).

  • dHYPO score of hypoglycemia severity developed by Ryan et al. (13).

  • eLability index measure of glycemic lability developed by Ryan et al. (13).

  • **P < 0.01 for comparison with T1D subjects before transplantation.